Skip to main content
TipRanks
Go Ultimate75% OFF

Saniona AB (30S) AI Stock Analysis

1 Followers
DE:30S

Saniona AB

(Frankfurt:30S)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetA debt-free balance sheet and substantial equity cushion reduce financial pressure and interest obligations. This gives Saniona greater flexibility to fund development programs, absorb operating volatility, and pursue partnerships without relying heavily on external borrowing.
Negative Factors
Severe revenue volatilitySharp changes in revenue make current earnings difficult to forecast and weaken confidence that recent profitability will persist. In a biotech model where licensing or milestone income may affect results, inconsistent top-line performance can complicate planning and pipeline investment.

Saniona AB (30S) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%DE:30S-29.22%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 142.55M
Dividend Yield
―
Average Volume (3M)
500
Price to Earnings (P/E)
8.6
Beta (1Y)
0.64
Revenue Growth
29.05%
EPS Growth
-30.33%
Country
Germany
Employees
44
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disord...

Saniona AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:30S against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CAMXSE:CAMX78OutperformSEK 44.36B57.6816.50%―2.96%-4.07%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.01B255.805.18%0.71%-46.09%-90.13%
SE:HNSASE:HNSA60NeutralSEK 4.87B-6.06――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR49NeutralSEK 852.21M10.17105.09%―――

* Healthcare Sector Average

Performance Comparison

0%200%400%DE:30SSE:HNSASE:MVIRSE:CAMXSE:ALZCURSE:BIOA.BDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:30S and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:30SSaniona AB1.07-0.46-30.33%
SE:HNSAHansa Biopharma47.8820.0672.11%
SE:MVIRMedivir1.090.65148.86%
SE:CAMXCamurus AB732.50118.0019.20%
SE:ALZCURAlzeCure Pharma AB6.104.32243.28%
SE:BIOA.BBioArctic AB Class B304.4021.687.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.